At the age of 52 I was diagnosed with an advanced small intestine malignant tumor and had a poor reaction to surgical treatment and chemotherapy. At the time of contacting Smartomica, I was referred to palliative care in UK. The molecular study carried out by the Smartomica team identified individual target proteins in the structure of the tumor.

A personalized treatment regimen has been developed, including immunotherapy, which was the first case approved by the UK Department of Health for this kind of treatment in small intestine tumors. Currently, in stable remission without signs of disease recurrence for more than 4 years under the supervision of Smartomica medical professionals.

I will remain (hopefully for some time) forever grateful.

Thank you.

After being newly diagnosed with cancer I was referred to Smartomica in 2019, looking for optimal treatment solutions. After a biopsy and a full molecular study, I was recommended to undergo local treatment by HiFu technique. I continued to receive adjuvant therapy based on repurposed drugs and reached full remission.

In 2021, during the monitoring program for Cancer Survivors in Smartomica, I was diagnosed with lung cancer. Due to the early stage at the moment of identification, I undertook pulmonary lobectomy followed by bespoke chemotherapy protocol which was based on the tumour molecular study results.

Currently in full remission.